Dr. Stephan Moll coauthored an article published on May 15, 2024 in the New England Journal of Medicine ( ) expanding on an earlier observation (Warkentin TE et al. ) that adenoviral infection can be associated with a clinical picture of severe thrombosis and thrombocytopenia, triggered by antibody formation against platelet factor 4 (PF4), similar to but distinct from heparin-induced thrombocytopenia, and similar to adeno-virus vector COVID-vaccine associated VITT (vaccine-induced immune thrombocytopenia).
The current study entitled 鈥�Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders鈥� further characterized the anti-PF4 antibodies from four patients with an adenoviral infection associated anti-PF4 disorder and found highly similar amino acid fingerprints of their antibodies鈥� antigen-binding sites, leading to superimposable molecular structures of these anti-PF4 antibodies with anti-PF4 antibodies identified in patients with vaccine-induced immune thrombocytopenia (VITT).